Bulk Inquiry
Nilotinib hydrochloride
- AMN 107 hydrochloride
- Parent CAS: 641571-10-0
- Soluble in DMSO
- MF: C28H22F3N7O.HCl
- MW: 565.98
Description
A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations.
The free base Nilotinib is also available as Axon 1396.
More Information
| Parent CAS No. | 641571-10-0 |
|---|---|
| Chemical Name | 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide hydrochloride |
| SMILES | C1C(N2C=C(C)N=C2)=CC(NC(=O)C2C=C(NC3N=C(C4C=CC=NC=4)C=CN=3)C(C)=CC=2)=CC=1C(F)(F)F.Cl |
| MFCD | N.A. |
| InChi | InChI=1S/C28H22F3N7O.ClH/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38;/h3-16H,1-2H3,(H,35,39)(H,33,36,37);1H |
| InChiKey | VTGGYCCJUPYZSX-UHFFFAOYSA-N |
| CID | 16006490 |
| Short Description | Bcr-Abl inhibitor |
References
- H Kantarjian et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354 (24), 2542–51.
- E Weisberg et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 2006, 94, 1765-1769.
- JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol. 2008, 119, 212-217.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1137 | PD180970 |
From $143.00 |
| 1392 | Dasatinib |
From $99.00 |
| 1394 | Imatinib mesylate |
From $66.00 |
| 1396 | Nilotinib |
From $55.00 |
| 1407 | SKI 606 |
From $82.50 |
| 1857 | AP 24534 |
From $77.00 |
| 1882 | GNF 2 |
From $121.00 |
| 2121 | INNO 406 |
From $93.50 |
| 2123 | Rebastinib |
From $121.00 |
| 2219 | AT 9283 |
From $99.00 |
| 2757 | Asciminib |
From $132.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.